When was Octave Bioscience founded?

Octave Bioscience was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Octave Bioscience located?

Octave Bioscience is headquartered in Menlo Park, United States.

Who is the current CEO of Octave Bioscience?

William Hagstrom and Doug Biehn s of Octave Bioscience. William Hagstrom has also founded 2 companies.

How many employees does Octave Bioscience have?

As of Sep 30, 2026, the latest employee count at Octave Bioscience is 97.

Is Octave Bioscience a funded company?

Octave Bioscience is a funded company, having raised a total of $124M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 13, 2017.

When was the latest funding round of Octave Bioscience?

Octave Bioscience's latest funding was a $***** Conventional Debt round on Sep 04, 2025, with participation from 1 investor.

Where does Octave Bioscience rank among its competitors?

Octave Bioscience ranks 1st amongst 55 active competitors, of which 13 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Amprion, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of Octave Bioscience?

Octave Bioscience's top competitors include Amprion, PeopleBio R&D and Nanostics. Among them, Amprion secured the most recent funding round in July, 2026.

Octave Bioscience - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of AI-based molecular diagnostic tools for neurodegenerative diseases. The company has developed the first blood test to measure disease activity at the biology level. The platform will captures data using sensors, wearables & mobile tools to identify changes in disease status and optimize images adding quantitation, serial trends.

Website: octavebio.com
Social
Email ID: *****@octavebio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

Menlo Park, United States

Stage

Series C

Total Funding

$124M in 9 rounds

Latest Funding Round

Conventional Debt, Sep 04, 2025, $*****

Investors

Novartis & 15 more

Ranked

1^st among 55 active competitors

Employee Count

97 as on Sep 30, 2026

Similar Companies

Amprion & 69 more

View Octave Bioscience's full profile

Octave Bioscience has raised a total funding of $124M over 9 rounds. Its first funding round was on Sep 13, 2017. Its latest funding round was a Conventional Debt round on Sep 04, 2025 for $*****. 1 investor participated in its latest round. Octave Bioscience has 16 institutional investors.

Here is the list of recent funding rounds of Octave Bioscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 04, 2025	3463697	Conventional Debt	8787735	6119200	9619402	2490012
Mar 07, 2025	4910592	Series C	6778394	2416205	9365849	Byers Capital & 8 more
Nov 16, 2023	3129578	Grant (prize money)	2353062	9199495	9566388	The Michael J. Fox Foundation

Access funding benchmarks and valuations. Sign up today!

View details of Octave Bioscience's funding rounds and investors

The founders of Octave Bioscience are William Hagstrom and Melinda Thomas. William Hagstrom and Doug Biehn are the CEOs of Octave Bioscience.

Here are the details of Octave Bioscience's key team members:

William Hagstrom: Co-Founder & CEO of Octave Bioscience and founder of 2 other companies, Quadrotian and Biolytx. They serve on the board of 1 company.
Contact Info: 1 email address
Melinda Thomas: Former Co-Founder & COO of Octave Bioscience.
Contact Info: 1 email address
Doug Biehn: CEO of Octave Bioscience.
Contact Info: 1 email address

View details of Octave Bioscience's Founder profiles and Board Members

Octave Bioscience's employee count trend

Octave Bioscience has 97 employees as of Sep 26. Here is Octave Bioscience's employee count trend over the years:

Employee count trend for Octave Bioscience

Uncover Octave Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Octave Bioscience include Amprion, PeopleBio R&D and Nanostics. Here is the list of Top 10 competitors of Octave Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Octave Bioscience 2014, Menlo Park (United States), Series C	Provider of AI-based molecular diagnostic tools for neurodegenrative diseases	$124M	Deerfield, Northpond Ventures & 14 others	66/100
2nd	Amprion 2006, Houston (United States), Series B	Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology	$11.8M	Formationve, Lilly & 3 others	56/100
3rd	PeopleBio R&D 2002, Seongnam-si (South Korea), Public	Immunoassays for early detection of neuro-degenerative diseases	-	DT&Investment, GNTech Venture Capital & 12 others	48/100
4th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-	indyRIOT	40/100
5th	Cytox 2007, Oxford (United Kingdom), Series B	Developer for prognostic tests for assessing the risk of dementia	$12.1M	Maven Capital Partners, Northwest Fund & 22 others	38/100
6th	Alseres Pharmaceuticals 1972, Auburndale (United States), Public	Therapeutic and diagnostic products for disorders in the central nervous system (CNS)	$4M	Ingalls and Snyder	35/100
7th	LikeMinds 2008, Boston (United States), Series A	Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases	$6.37M	-	35/100
8th	Durin Life Sciences 2010, United States, Acquired	Early disease detection blood tests for Alzheimer's and Parkinson's	$5.5M	-	34/100
9th	Durin Technologies 2010, Camden (United States), Series B	Developer of the diagnostic test for neurodegenerative diseases	$8.05M	Breakthrough Diagnostics	32/100
10th	Gene Solutions 2006, Charlottesville (United States), Series A	Pioneering mitochondrial medicine, developing therapeutics for neurodegenerative and muscular diseases	$6.33M	-	32/100